Kirsten Vandercruyssen

Kirsten Vandercruyssen Contact info

Kirsten Vandercruyssen

Drug Quality and Registration (DruQuaR) group
Ottergemsesteenweg 460, 9000 Ghent (Belgium)

Phone: + 32 (0)9 264.80.99 (secr. 81.01)
Fax: + 32 (0)9 264.81.93
E-mail: Kirsten.Vandercruyssen@UGent.be

 

 

Ph.D. research


Title: Pharmaceutical development of 1,2,4-trioxane derivatives in polymers.

Summary:

The artemisinin semi-synthetic derivatives, i.e. artesunate, artemether and dihydroartemisinin are known for their great anti-malarial activity and are recommended as first-line treatment by the World Health Organisation (WHO). Next to their anti-malarial activity, it has recently been proven that those substances have a therapeutic efficacy in other tropical neglected diseases such as schistosomiasis and leihmaniasis. In addition, anticancer activity has been revealed. But this chemical group possess a low intrinsic stability and a great reactivity with pharmaceutical recipients: not only the peroxide bridge but also the specific side chain are subjected to degradation. Secondly, a great pharmacokinetic variability is consistently noticed which has negative consequences for therapeutic results.

Those bottlenecks will be further explored in this Ph.D. whereby an analytical-pharmaceutical approach is applied. The new formulations aim at increased stability profile and modify the pharmacokinetic profile of the artemisinins, resulting in enhanced therapeutic results.

Keywords: artemisinin derivatives, stability, formulation, farmacokinetic

Publications